Anagenics Limited (AU:AN1)
ASX:AN1
Top Page
Anagenics
(Sydney:AN1)
Select Model
Select Model
Rating:44Neutral
Price Target:―
Action:ReiteratedDate:12/30/25
The score is primarily constrained by weak financial performance—persistent losses, continued negative operating/free cash flow, and a significant latest-year revenue decline—despite only moderate leverage. Technical and valuation inputs were not available, so they were treated neutrally and did not materially offset the financial risks.
Positive Factors
Improved Cash Flow
Improved cash flow from restructuring indicates better financial management, enhancing the company's ability to fund operations and growth.
Negative Factors
Persistent Losses
Persistent losses and cash burn indicate financial instability, challenging the company's ability to sustain operations without external funding.
Read all positive and negative factors
Positive Factors
Negative Factors
Improved Cash Flow
Improved cash flow from restructuring indicates better financial management, enhancing the company's ability to fund operations and growth.
Read all positive factors
Anagenics (AN1) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$4.93M
Dividend YieldN/A
Average Volume (3M)N/A
Price to Earnings (P/E)5.6
Beta (1Y)0.92
Revenue Growth-54.87%
EPS Growth86.17%
CountryAU
Employees11
SectorConsumer Defensive
Sector Strength42
IndustryHousehold & Personal Products
Share Statistics
EPS (TTM)0.00
Shares Outstanding985,450,800
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)1.28
Price to Sales (P/S)0.49
P/FCF Ratio-1.49
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Anagenics Business Overview & Revenue Model
Company Description
Anagenics Limited operates as a health and beauty-tech company in Australia, New Zealand, Japan, and internationally. The company develops and sales FGF5 inhibitor hair health and hair growth products under the evolis, evolis Professional, Lexilis...
How the Company Makes Money
Anagenics generates revenue primarily through the sale of its proprietary health and wellness products in various markets. The company's revenue streams include direct sales to consumers through online platforms, partnerships with retail distribut...
Anagenics Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
42
Neutral
Cash Flow
16
Very Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 4.70M | 4.75M | 10.80M | 9.11M | 6.95M | 5.82M |
| Gross Profit | 2.10M | 2.04M | 4.36M | 4.05M | 3.80M | 3.70M |
| EBITDA | 349.34K | -994.77K | -6.60M | -1.80M | -2.62M | -3.90M |
| Net Income | -645.06K | -1.24M | -7.49M | -2.67M | -3.65M | -3.39M |
Balance Sheet | ||||||
| Total Assets | 4.10M | 4.10M | 6.19M | 11.11M | 12.92M | 13.29M |
| Cash, Cash Equivalents and Short-Term Investments | 294.30K | 395.52K | 1.62M | 2.57M | 3.28M | 6.73M |
| Total Debt | 986.80K | 848.05K | 772.64K | 654.33K | 1.76M | 1.43M |
| Total Liabilities | 1.82M | 2.28M | 3.48M | 2.22M | 4.64M | 2.86M |
| Stockholders Equity | 2.27M | 1.83M | 2.71M | 8.90M | 8.29M | 10.43M |
Cash Flow | ||||||
| Free Cash Flow | -953.41K | -1.58M | -1.84M | -1.83M | -2.59M | -4.19M |
| Operating Cash Flow | -942.12K | -1.58M | -1.74M | -1.78M | -2.55M | -4.17M |
| Investing Cash Flow | -11.30K | 0.00 | -197.90K | -1.51M | -968.20K | 477.53K |
| Financing Cash Flow | 656.17K | 345.41K | 993.72K | 2.56M | 73.31K | 3.50M |
Anagenics Peers Comparison
UnderperformOutperform
Sector (62)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
45 Neutral | AU$12.00M | -0.26 | 2542.90% | ― | 12.92% | 34.21% | |
44 Neutral | AU$4.93M | 5.63 | -54.48% | ― | -54.87% | 86.17% | |
44 Neutral | AU$1.72M | -0.44 | -139.90% | ― | ― | ― | |
42 Neutral | AU$6.66M | -0.01 | 226.76% | ― | -21.84% | 79.99% | |
41 Neutral | AU$8.04M | -1.62 | -44.35% | ― | -18.70% | 20.83% | |
39 Underperform | AU$23.17M | -33.08 | -321.20% | ― | 6.76% | ― |
* Consumer Defensive Sector Average
AU:AN1
Anagenics
―
―
―
AU:EVE
EVE Health Group Limited
0.02
>-0.01
-23.33%
AU:SKN
Skin Elements Limited
―
―
―
AU:HCT
Holista Colltech Limited
0.06
0.03
80.00%
AU:NGS
Nutritional Growth Solutions Ltd.
0.02
>-0.01
-33.33%
AU:HPC
Hydration Pharmaceuticals Co. Ltd.
0.01
0.00
0.00%
Anagenics Corporate Events
Anagenics Appoints Connect National Audit as New External Auditor
Dec 29, 2025
Anagenics Limited has announced a change of auditor, with William Buck Audit (Vic) Pty Ltd resigning as the company’s auditor following consent from the Australian Securities and Investments Commission, effective 24 December 2025. Connect Na...
Anagenics Calls January 2026 Meeting to Ratify Share Placement
Dec 24, 2025
Anagenics Limited has called a general meeting of shareholders for 29 January 2026 in Sydney to consider ratifying a recent equity placement to sophisticated investors. The board is seeking shareholder approval under ASX Listing Rule 7.4 for the p...
Anagenics Seeks ASX Quotation for 74.4 Million New Shares
Dec 21, 2025
Anagenics Limited has applied to the ASX for quotation of 74,448,054 new fully paid ordinary shares under its AN1 ticker. The shares, issued on 22 December 2025 as part of a previously flagged transaction, will significantly expand the companyR...
Anagenics Files Cleansing Prospectus to Enable Trading of Placement Shares
Dec 21, 2025
Anagenics Limited has lodged a transaction-specific cleansing prospectus for a small offer of up to 100,000 new shares at $0.0046 each to raise a nominal $460, primarily to satisfy regulatory requirements rather than to fund operations. The docume...
Anagenics Limited Announces Proposed Securities Issue
Dec 10, 2025
Anagenics Limited has announced a proposed issue of 414,682,381 ordinary fully paid securities, scheduled for February 5, 2026. This move is part of a placement or other type of issue, and the company has submitted the necessary information to the...
Anagenics Limited Announces Proposed Securities Issue
Dec 10, 2025
Anagenics Limited has announced a proposed issue of 74,448,054 ordinary fully paid securities, with the issuance date set for December 22, 2025. This move is part of a placement or other type of securities issue, and the company has applied for th...
Anagenics Limited Secures A$2.25 Million Through Share Placement
Dec 10, 2025
Anagenics Limited has announced a two-tranche placement to raise A$2.25 million by issuing approximately 489 million new shares at $0.0046 each, an 8% discount to the recent average price. The funds will support brand expansion, new business oppor...
Anagenics Limited Initiates Trading Halt Ahead of Capital Raising Announcement
Dec 8, 2025
Anagenics Limited has requested a trading halt on its securities pending an announcement regarding a significant capital raising. The halt is expected to last until the announcement is made or until normal trading resumes on December 10, 2025. Thi...
Anagenics Limited Successfully Passes All Resolutions at 2025 AGM
Nov 25, 2025
Anagenics Limited announced that all resolutions proposed at its 2025 Annual General Meeting were approved by the necessary majority. This includes the adoption of the remuneration report, re-election of a director, appointment of an auditor, and ...
Anagenics Limited Successfully Passes All Resolutions at 2025 AGM
Nov 25, 2025
Anagenics Limited announced that all resolutions proposed at its 2025 Annual General Meeting were passed by the requisite majority. The resolutions included the adoption of the remuneration report, re-election of a director, appointment of an audi...
Anagenics Regains Control Over Midkine Portfolio Following Licence Termination
Nov 3, 2025
Anagenics Limited has announced the termination of its Licence Agreement with Lyramid Pty Ltd, now owned by Roquefort Therapeutics, regarding its Midkine intellectual property portfolio. This termination, effective from 2 November 2025, allows Ana...
Anagenics Reports Improved Cash Flow and Strong Brand Performance
Oct 31, 2025
Anagenics Limited reported a significant improvement in operating cash outflows for the quarter ending September 2025, attributed to a successful business restructuring. The company reduced costs across staff, advertising, and administration, alig...
Anagenics Limited Announces 2025 AGM Agenda
Oct 17, 2025
Anagenics Limited has announced its 2025 Annual General Meeting, scheduled for November 25, 2025, in Sydney. Key agenda items include the re-election of a non-executive director, adoption of the Remuneration Report, appointment of an auditor, and ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.